Chemomab Therapeutics (CMMB) Depreciation & Amortization (CF) (2018 - 2023)

Chemomab Therapeutics (CMMB) has 6 years of Depreciation & Amortization (CF) data on file, last reported at $16000.0 in Q4 2023.

• Quarterly Depreciation & Amortization (CF) rose 14.29% year-over-year to $16000.0 in Q4 2023, while the trailing twelve-month figure through Sep 2024 was $16000.0 (down 75.38% YoY) and the FY2025 annual result came in at $70000.0, up 32.08% from the prior year.
• Depreciation & Amortization (CF) retreated to $16000.0 in Q4 2023, from $19000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $211000.0 in Q4 2019 to a low of $5000.0 in Q1 2020.
• A 5-year average of $23200.0 and a median of $14000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2019 — Depreciation & Amortization (CF) soared 955.0% — and 2020, when it sank 97.16%.
• Tracing CMMB's Depreciation & Amortization (CF) over 5 years: stood at $211000.0 in 2019, then slumped by 97.16% to $6000.0 in 2020, then surged by 83.33% to $11000.0 in 2021, then climbed by 27.27% to $14000.0 in 2022, then increased by 14.29% to $16000.0 in 2023.
• The last three Depreciation & Amortization (CF) figures came in at $16000.0 (Q4 2023), $19000.0 (Q3 2023), and $16000.0 (Q2 2023), per Business Quant data.